Related Experiment Video
Updated: Mar 20, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Nicotinamide and phosphate homeostasis in chronic kidney disease
Charles Ginsberg1, Joachim H Ix
1aDivision of Nephrology-Hypertension, Department of Medicine, University of California San Diego bNephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California cDivision of Preventive Medicine, Department of Family Medicine and Public Health, University of California San Diego, San Diego, California, USA.
Purpose Of Review:
Higher serum phosphate concentration is a central driver of the chronic kidney disease (CKD) mineral bone disorder (MBD). Although phosphate binders are commonly used to lower phosphate, they are minimally effective in CKD. Nicotinamide (vitamin B3) decreases intestinal phosphate transport in animals. Its efficacy and safety in CKD is uncertain.
Recent Findings:
We review data differentiating nicotinamide from nicotinic acid (niacin) and compare the metabolism and side-effect profile of each. Several recent studies have tested the safety and efficacy of nicotinamide in patients with CKD and the general population. Available data on efficacy and safety, gaps in knowledge, and ongoing studies to address them are described.
Summary:
Nicotinamide is a novel potential tool to treat hyperphosphatemia in patients with CKD, but additional data on safety and efficacy are required before widespread clinical use.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Acute Kidney Injury V: Interprofessional Care

